Methods for vaccinating against malaria
AssigneesGlaxosmithkline Biologicals SA, The United States of America as represented by the Secretary of the Navy
InventorsStephen Hoffman, Ruobing Wang, Judith Epstein, Joseph Cohen
Life of this patent
Estimating the term…
Abstract
The invention pertains to methods for protecting against malaria infection by vaccination. The method of the invention involves priming an anti-malaria immune response with a DNA-based vaccine and boosting that response with a protein-based a vaccine. The method of the invention also relates to broadening the resulting immune response by boosting with a protein-based vaccine.
Claims44
A method for immunizing a human against a malaria-causing pathogen comprising:
- a) priming an immune response in a human by administering a priming vaccine comprising at least one polynucleotide encoding at least one first malaria antigen in a priming dose effective to establish the response;
- and
- b) boosting the primed immune response in the human by subsequently administering a boosting vaccine comprising at least one polypeptide which comprises at least one second malaria antigen having at least one epitope in common with the at least one first malaria antigen in a boosting dose effective to boost the primed immune response
- wherein administration of the priming vaccine primes CD8+ T cells and administration of the boosting vaccine recalls the primed CD8+ T cells, broadens the primed CD8+ T cell response, and results in the generation of anti-malaria CD8+ T cells, anti-malaria CD4+ T cells, and anti-malaria antibodies.
A kit for immunizing a human against a malaria-causing pathogen comprising:
- a) a priming vaccine comprising at least one polynucleotide encoding at least one first malaria antigen;
- and
- b) a boosting vaccine comprised of at least one polypeptide further comprising at least one second malaria antigen having at least one epitope in common with the at least one first malaria antigen
- wherein administration of the priming vaccine primes CD8+ T cells and administration of the boosting vaccine recalls the primed CD8+ T cells, broadens the primed CD8+ T cell response, and results in the generation of anti-malaria CD8+ T cells, anti-malaria CD4+ T cells, and anti-malaria antibodies.
A kit for immunizing a human against a malaria-causing pathogen comprising:
- a) a priming vaccine comprising at least one polynucleotide encoding substantially all of the CS protein or a fragment thereof;
- and
- b) a boosting vaccine comprising at least one polypeptide comprising substantially all of the CS protein or a fragment thereof.
A vaccine comprising, as separate components, a priming composition comprising at least one polynucleotide encoding substantially all of the CS protein or a fragment thereof and a boosting composition comprising at least one polypeptide comprising substantially all of the CS protein or a fragment thereof.
A method for immunizing a human against a malaria-causing pathogen comprising:
- a) priming an immune response in a human by administering a priming vaccine comprising at least one polynucleotide encoding substantially all of the CS protein or a fragment thereof in a priming dose effective to establish the immune response;
- and
- b) boosting the primed immune response in the human by subsequently administering a boosting vaccine comprising at least one polypeptide comprising substantially all of the CS protein or a fragment thereof in a boosting dose effective to boost the primed immune response.
Dependencies are inferred from the claim text.